INSPECS Group plc (AIM:SPEC)
London · Delayed Price · Currency is GBP · Price in GBX 82.00
-1.50 (-1.80%)
May 27, 2026, 2:03 PM GMT
INSPECS Group Market Cap
INSPECS Group has a market cap or net worth of 84.9 million as of May 27, 2026. Its market cap has increased by 96.47% in one year.
Market Cap
84.90M
Enterprise Value
128.69M
Revenue
191.70M
Ranking
n/a
PE Ratio
n/a
Stock Price
82.00
Market Cap Chart
Since February 27, 2020, INSPECS Group's market cap has decreased from 137.95M to 84.90M, a decrease of -38.46%. That is a compound annual growth rate of -7.48%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 26, 2026 | 84.90M | 16.78% |
| Dec 31, 2025 | 72.70M | 57.14% |
| Dec 31, 2024 | 46.26M | -45.83% |
| Dec 29, 2023 | 85.40M | 95.35% |
| Dec 30, 2022 | 43.72M | -88.33% |
| Dec 31, 2021 | 374.78M | 12.12% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Feb 27, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 216.52B |
| GSK plc | 76.85B |
| Haleon | 30.29B |
| Smith & Nephew | 9.68B |
| Faron Pharmaceuticals Oy | 89.78M |
| Bioventix | 88.82M |
| Ondine Biomedical | 77.93M |
| 4basebio | 75.07M |